Nanotherapeutic macrophage-based immunotherapy for the peritoneal carcinomatosis of lung cancer-Reference-Cited by-同舟云学术

Nanotherapeutic macrophage-based immunotherapy for the peritoneal carcinomatosis of lung cancer

Published:2022 Issue:6 Volume:14 Page:2304-2315
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Wang Yonghui¹²³,Chen Binfan¹²,He Zhidi¹²⁴,Tu Bin¹²³,Zhao Pengfei¹,Wang Huiyuan¹,Asrorov Akmal¹⁵^ORCID,Muhitdinov Bahtiyor¹⁵,Jiang Jizong¹⁶,Huang Yongzhuo¹²³⁷^ORCID

Affiliation:

1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

2. University of Chinese Academy of Sciences, Beijing 100049, China

3. Zhongshan Institute for Drug Discovery, SIMM, CAS, Zhongshan 528437, China

4. Department of Cancer Biotherapy Center, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, 650118, P.R. China

5. Institute of Bioorganic Chemistry Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan

6. Shanghai University School of Medicine, Shanghai 200444, China

7. NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients, Shanghai 201203, China

Abstract

In this “two-birds-one stone” strategy using celastrol NP-containing M1Φ, M1Φ serves as not only a cell therapeutic agent but also a carrier for celastrol NPs that, in turn, facilitate M1 polarization. The exocytosed NPs can also kill tumor cells.

Funder

National Key Research and Development Program of China

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2022/NR/D1NR06518A

Reference29 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Small bowel metastases from primary carcinoma of the lung